Global Tumor Markers Testing Market, By Types (Human Chorionic Gonadotropin (HCG or b-HCG), Cancer Antigen 15-3 (CA15-3), Alpha-Fetoprotein (AFP), Carbohydrate Antigen 19-9 (CA19-9), Cancer Antigen 125 (CA125), Carcinoembryonic Antigen (CEA), Prostate-Specific Antigen (PSA)), Organ (Bladder, Breast, Colorectal, Gastrointestinal, Liver, Lung, Oral, Ovarian, Pancreatic, Prostatic, Skin Testicular Cancer, Leukemia, Lymphoma, Others), End-Users (Hospitals, Commercial or Private Laboratories, Physician Offices or Group Practices, Ambulatory Care Centers), Products (Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains, Others), Methods (Screening, Imaging, Theranostics, Signoidoscopy, Others) - Industry Trends and Forecast to 2030.
Tumor Markers Testing Market Analysis and Size
Cancer is one of the top causes of death globally, with a higher incidence in developed and developing markets. Technological advancements in diagnostic tests are anticipated to accelerate industry growth as healthcare professionals focus on developing effective screening and treatment solutions to check prevalence levels. Different healthcare professionals primarily focus on developing effective screening and treatment solutions to evaluate the prevalence levels. Several healthcare agencies and market players are launching different programs promoting different advanced diagnostics, thus accelerating market growth.
Data Bridge Market Research analyses the tumor markers testing market growth rate in 2023-2030. The expected CAGR of the tumor markers testing market is around 7.70% in the mentioned forecast period. The market was valued at USD 16.7 billion in 2022 and would grow to USD 30.23 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Tumor Markers Testing Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Types (Human Chorionic Gonadotropin (HCG or b-HCG), Cancer Antigen 15-3 (CA15-3), Alpha-Fetoprotein (AFP), Carbohydrate Antigen 19-9 (CA19-9), Cancer Antigen 125 (CA125), Carcinoembryonic Antigen (CEA), Prostate-Specific Antigen (PSA)), Organ (Bladder, Breast, Colorectal, Gastrointestinal, Liver, Lung, Oral, Ovarian, Pancreatic, Prostatic, Skin Testicular Cancer, Leukemia, Lymphoma, Others), End-Users (Hospitals, Commercial or Private Laboratories, Physician Offices or Group Practices, Ambulatory Care Centers), Products (Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains, Others), Methods (Screening, Imaging, Theranostics, Signoidoscopy, Others)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Abbott. (U.S.), DiagnoCure Inc. (Canada), Thermo Fisher Scientific (U.S.), Illumina, Inc. (U.S.), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (U.S.), Quest Diagnostics Incorporated. (U.S.), Merck KGaA, (Germany), Hologic, Inc. (U.S.), B.D. (U.S.), GSK plc. (U.K.), Novartis AG (Switzerland), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.), Pfizer, Inc. (U.S.), Genomic Health, Inc. (U.S.), bioMérieux S.A. (France), Bio-Rad Laboratories, Inc (U.S.)., Cepheid (U.S.), Leica Biosystems Nussloch GmbH (Germany), Ortho Clinical Diagnostics (U.S.)., Panacea Biotec (India)., Siemens (Germany), Takara Bio Inc (Japan)., Takeda Pharmaceutical Company Limited (Japan)
|
|
Market Opportunities
|
|
Market Definition
A tumor marker test measures the number of substances in the blood, tissue, urine, or other body fluids. Most tumor markers are proteins made by both normal cells and cancer cells, but they are made in higher amounts by cancer cells. A tumor marker is a naturally occurring substance in the body. It is a material found in the blood, urine, or body tissue. They are the mutations, changes, or patterns in a tumor's DNA.
Tumor Markers Testing Market Dynamics
Drivers
- Increased Technological Advancements in Tumor Markers Testing
Technological advancements in diagnostic testing are anticipated to boost market growth. For instance, Hologic, Inc. announced the commercial accessibility of the Genius Digital Diagnostics System in Europe in 2021. This next-generation cervical cancer screening system incorporates deep learning-based A.I. with innovative volumetric imaging technology to identify cervical cancer cells and pre-cancerous lesions in women. Thus, this is expected to boost market growth.
- Increasing Strategic Collaborations Associated with Tumor Markers Testing
There is an increase in collaborations and acquisitions regarding tumor marker testing products. For instance, in 2022, the Precision Cancer Consortium (PCC) collaborated with pharmaceutical companies by enabling access to comprehensive testing for all cancer patients globally. The PCC runs many initiatives to surge patient access to precision diagnostics through wide-ranging genomic testing, which includes NGS. Thus, this boosts the market growth
Opportunities
- Growing Awareness Programs by Major Organizations
An increasing number of programs to raise awareness regarding malignant tumor screening in various organizations is a primary factor responsible for the increasing demand for diagnostic products worldwide. Various countries have undertaken numerous measures to increase early screening and help patients. For instance, the Indian government launched the Prime Minister's National Relief Fund and Ayushman Bharat for patients that require treatment assistance. Thus, this factor boosts market growth.
- Increasing Prevalence of Cancer
Cancer is one of the top causes of death worldwide, resulting in around 10 million deaths in 2020. In 2021, there were around 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the U.S. Furthermore, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in 2022. This leads to higher usage of tumor market testing. This testing is done rapidly with the rising cancer cases to identify the cancer cells and improve patient recovery. Thus, this factor helps in the growth of the market.
Restraints/Challenges
- High Cost of Tumor Marker Testing
Numerous hospitals in underdeveloped and developing nations cannot invest in diagnostic imaging equipment due to high costs and budgetary constraints. Though, due to the growing demand for tumor testing worldwide, hospitals that cannot afford to buy new and advanced imaging systems favor rebuilt ones. Thus, this factor restraints the market growth.
This tumor markers testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Tumor markers testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2021, Agilent acquired Resolution Bioscience Inc. The acquisition extends and complements the company's competencies in NGS-based cancer diagnostics and offers the company with advanced technology to meet the needs of the growing and developing market.
Global Tumor Markers Testing Market Scope
The tumor markers testing market is segmented based on types, organ, end users, products and methods. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Human Chorionic Gonadotropin (HCG or b-HCG)
- Cancer Antigen 15-3 (CA15-3)
- Alpha-Fetoprotein (AFP)
- Carbohydrate Antigen 19-9 (CA19-9)
- Cancer Antigen 125 (CA125)
- Carcinoembryonic Antigen (CEA)
- Prostate-Specific Antigen (PSA)
Organ
- Bladder
- Breast
- Colorectal
- Gastrointestinal
- Liver
- Lung
- Oral,
- Ovarian
- Pancreatic
- Prostatic
- Skin Testicular Cancer
- Leukemia
- Lymphoma
- Others
End User
- Hospitals
- Commercial or Private Laboratories
- Physician Offices or Group Practices
- Ambulatory Care Centers
Products
- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains
- Others
Methods
- Screening
- Imaging
- Theranostics
- Signoidoscopy
- Others
Tumor Markers Testing Market Regional Analysis/Insights
The tumor markers testing market is analyzed and market size insights and trends are provided by types, organ, end users, products and methods as referenced above.
The major countries covered in the tumor markers testing market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market because of the region's increased acceptance of tumor markers. Also, increasing strategic activities by major market players are driving the market in this region.
Asia Pacific is projected to witness huge growth in the market due to the rise in tumor incidence. Additionally, the increase in the alertness and affordability for an advanced tumor is expected to boost further the growth of the tumor markers testing market in the region during the forecast period.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Tumor Markers Testing Market Share Analysis
The tumor markers testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related tumor markers testing market.
Key players operating in the tumor markers testing market include:
- Abbott. (U.S.)
- DiagnoCure Inc. (Canada)
- Thermo Fisher Scientific (U.S.)
- Illumina, Inc. (U.S.)
- QIAGEN (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Agilent Technologies, Inc. (U.S.)
- Quest Diagnostics Incorporated. (U.S.)
- Merck KGaA (Germany)
- Hologic, Inc. (U.S.)
- B.D. (U.S.)
- GSK plc. (U.K.)
- Novartis AG (Switzerland)
- Bristol-Myers Squibb Company (U.S.)
- Lilly (U.S.)
- Pfizer, Inc. (U.S.)
- Genomic Health, Inc. (U.S.)
- bioMérieux SA (France)
- Bio-Rad Laboratories, Inc (U.S.)
- Cepheid (U.S.)
- Leica Biosystems Nussloch GmbH (Germany
- Ortho Clinical Diagnostics (U.S.)
- Panacea Biotec (India)
- Siemens (Germany)
- Takara Bio Inc (Japan)
- Takeda Pharmaceutical Company Limited (Japan)
SKU-